Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats

British Journal of Pharmacology

Volumn 139, Issue 1, 2003, Pages 81-88

  Park, K S ^a   Li, Y ^a   Zhang, Y ^a   Gerbes, A L ^b   Liu, H ^a   Swain, M G ^a   Lee, S S ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c NONE   (Canada)

Author keywords

Atrial natriuretic peptide; cGMP; Cirrhosis; Endothelin 1; Hyperdynamic circulation; Renal dysfunction; Sodium retention

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; ENDOTHELIN 1; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MICROSPHERE; PROTEINASE INHIBITOR; SINORPHAN; THIORPHAN; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BILE DUCT LIGATION; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART OUTPUT; INULIN CLEARANCE; ISOTOPE LABELING; KIDNEY FUNCTION; LIVER CIRRHOSIS; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; SODIUM RETENTION;

EID: 0038392669     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705219     Document Type: Article

References (48)

1. ABASSI, Z., GOLOMB, E. & KEISER, H.R. (1992). Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism, 41, 683 - 685.
2. ANDERSON, W.P., KORNER, P.I. & SELIG, S.E. (1981). Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. J. Physiol., 321, 21 - 30
3. ASBERT, M., GINES, A., GINES, P., JIMENEZ, W., CLARIA, J., SALO, J., ARROYO, V., RIVERA, F. & RODES, J. (1993). Circulating levels of endothelin in cirrhosis. Gastroenterology, 104, 1485 - 1491.
4. +-ATPase inhibition by atrial natriuretic factor in rat renal medulla. J. Physiol. Pharmacol., 49, 271 - 283.
5. BUTTERWORTH, R.F. (2000). Complications of cirrhosis III. Hepatic encephalopathy. J. Hepatol., 32, 171 - 180.
6. CAPASSO, G., UNWIN, R., CIANI, F., RIZZO, A., RUSSO, F., PICA, A. & DE SANTO, N.G. (2000). Inhibition of neutral endopeptidase potentiates the effects of atrial natriuretic peptide on acute cyclosporin-induced nephrotoxicity. Nephron, 86, 298 - 305.
7. DANILEWICZ, J.C., BARCLAY, P.L., BARNISH, I.T., BROWN, D., CAMPBELL, S.F., JAMES, K., SAMUELS, G.M., TERRETT, N.K. & WYTHES, M.J. (1989). UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem. Biophys. Res. Commun., 164, 58 - 65.
8. DUSSAULE, J.C., GRANGE, J.D., WOLF, J.P., LECOMTE, J.M., GROS, C., SCHWARTZ, J.C., BODIN, F. & ARDAILLOU, R. (1991). Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J. Clin. Endocrinol. Metab., 72, 653 - 659.
9. ERDOS, E.G. & SKIDGEL, R.A. (1989). Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J., 3, 145 - 151.
10. FALLON, M.B. & ABRAMS, G.A. (2000). Pulmonary dysfunction in chronic liver disease. Hepatology, 32, 859 - 865.
11. GARCIA-ESTAN, J., ORTIZ, M.C. & LEE, S.S. (2002). Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin. Sci. (London), 102, 213 - 222.
12. GERBES, A.L. (1993). The role of atrial natriuretic peptide (ANP) in chronic liver disease. Pharmacol, Ther., 58, 381 - 390.
13. GORNY, D., KORZENIOWSKA, J., MARCINIAK, A. & PIELECKI, J. (1994). Reducing effect of atrial natriuretic factor on Na, K-ATPase activity in rat kidney. J. Physiol. Pharmacol., 45, 173 - 181.
14. GROS, C., SOUQUE, A., SCHWARTZ, J.C., DUCHIER, J., COURNOT, A., BAUMER, P. & LECOMTE, J.M. (1989). Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan. Proc. Natl. Acad. Sci. U.S.A., 86, 7580 - 7584.
15. GUNNING, M., SILVA, P., BRENNER, B.M. & ZEIDEL, M.L. (1989). Characteristics of ANP-sensitive guanylate cyclase in inner medullary collecting duct cells. Am. J. Physiol., 256, F766 - F775.
16. HARTLEB, M., MICHIELSEN, P.P. & DZIURKOWSKA-MAREK, A. (1997). The role of nitric oxide in portal hypertensive systemic and portal vascular pathology. Acta Gastroenterol. Belg., 60, 222 - 232.
17. HAYNES, W.G. & WEBB, D.J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 344, 852 - 854.
18. HELMY, A., JALAN, R., NEWBY, D.E., JOHNSTON, N.R., HAYES, P.C. & WEBB, D.J. (2001), Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology, 33, 826 - 831.
19. KENNY, A.J., BOURNE, A. & INGRAM, J. (1993). Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J., 291, 83 - 88.
20. KHUNDMIRI. S.J. & LEDERER, E. (2002). PTH and DA regulate Na-K ATPase through divergent pathways. Am. J. Physiol. Renal. Physiol., 282, F512 - F522.
21. LANG, C.C., MOTWANI, J.G., COUTIE, W.J. & STRUTHERS, A.D. (1992). Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin. Sci. (London), 82, 619 - 623.
22. LEE, S.S. (1989). Cardiac abnormalities in liver cirrhosis. West. J. Med., 151, 530 - 535.
23. LEE, S.S., GIROD, C., BRAILLON, A., HADENGUE, A. & LEBREC, D. (1986). Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am. J. Physiol., 251, G176 - G180.
24. LIU, H. & LEE, S.S. (1999). Cardiopulmonary dysfunction in cirrhosis. J. Gastroenterol. Hepatol., 14, 600 - 608.
25. LOVE, M.P., HAYNES, W.G., GRAY, G.A., WEBB, D.J. & MCMURRAY, J.J. (1996). Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation, 94, 2131 - 2137.
26. MARTINEZ-PRIETO, C., ORTIZ, M.C. FORTEPIANI, L.A., RUIZ-MACIA, J., ATUCHA, N.M. & GARCIA-ESTAN, J. (2000). Haemodynamic and renal evolution of the bile duct-ligated rat. Clin. Sci. (London), 98, 611 - 617.
27. MOLLER, S., BENDTSEN, F. & HENRIKSEN, J.H. (2001). Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can. J. Gastroenterol., 15, 94 - 106.
28. MOLLER, S., GULBERG, V., HENRIKSEN, J.H. & GERBES, A.L. (1995). Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J. Hepatol., 23, 135 - 144.
29. MURPHY, L.J., CORDER, R., MALLET, A.I. & TURNER, A.J. (1994). Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br. J. Pharmacol., 113, 137 - 142.
30. NONOGUCHI, H., KNEPPER, M.A. & MANGANIELLO, V.C. (1987). Effects of atrial natriuretic factor on cyclic guanosine monophosphate and cyclic adenosine monophosphate accumulation in microdissected nephron segments from rats. J. Clin. Invest., 79, 500 - 507.
31. OHSUGA, M., MOREAU, R., HARTLEB, M., KOMEICHI, H. & LEBREC, D. (1994). Blunted systemic, splanchnic, and renal hemodynamic responses to atrial natriuretic peptide in rats with cirrhosis. J. Hepatol., 20, 91 - 96.
32. PAK, J.M. & LEE, S.S. (1994). Glucagon in portal hypertension. J. Hepatol., 20, 825 - 832.
33. SCAVONE, C., SCANLON, C., MCKEE, M. & NATHANSON, J.A. (1995). Atrial natriuretic peptide modulates sodium and potassium-activated adenosine triphosphatase through a mechanism involving cyclic GMP and cyclic GMP-dependent protein kinase. J. Pharmacol. Exp. Ther., 272, 1036 - 1043.
34. SCHWARTZ, J.C., GROS, C., LECOMTE, J.M. & BRALET, J. (1990). Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci., 47, 1279 - 1297.
35. SKIDGEL, R.A., ENGELBRECHT, S., JOHNSON, A.R. & ERDOS, E.G. (1984). Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides, 5, 769 - 776.
36. SOLTER, P., SISSON, D., THOMAS, W. & GOETZE, L. (2000). Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure. J. Pharmacol. Exp. Ther., 293, 989 - 995.
37. STEPHENSON, S.L. & KENNY, A.J. (1987). The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem. J., 243, 183 - 187.
38. SYREN, M.L. (1997). Effect of atrial natriuretic factor and fate of cyclic-guanosine-monophosphatc in the rat kidney. Acta physiol. Scand., 160, 1 - 7.
39. SYREN, M.L., TIRELLI, A.S., ASSAEL, B.M. & SERENI, F. (1996). Regulation of sodium-potassium-adenosine-triphosphatase activity by extracellular guanosine 3′, 5′-cyclic monophosphate in rat kidney. Acta Physiol. Scand., 158, 295 - 296.
40. TAUSSKY, H.H. & SHORR, E. (1953). A microcolorimetric method for the determination of inorganic phosphorus. J. Biol. Chem., 202, 675 - 685.
41. TRAPANI, A.J., BELL, M.E., COTE, D.T., DE LOMBAERT, S., ERION, M.D., GERLOCK, T.E., GHAI, R.D., HOPKINS, M.F., PEPPARD, J.V., WEBB, R.L., LAPPE, R.W. & WORCEL, M. (1994). Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. J. Cardiovasc. Pharmacol., 23, 358 - 364.
42. TRAPANI, A.J., SMITS, G.J., MCGRAW, D.E., SPEAR, K.L., KOEPKE, J.P., OLINS, G.M. & BLAINE, E.H. (1989). Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J. Cardiovasc. Pharmacol., 14, 419 - 424.
43. TSAI, Y.T., LIN, H.C. & LEE, S.D. (1997). Recent advances in the pathophysiology of portal hypertension. J. Gastroenterol. Hepatol., 12, S283 - S287.
44. URAYAMA, O. & NAKAO, M. (1979). Organ specificity of rat sodium- and potassium-activated adenosine triphosphatase. J. Biochem. (Tokyo), 86, 1371 - 1381.
45. WIEST, R. & GROSZMANN, R.J. (1999). Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin. Liver Dis., 19, 411 - 426.
46. WILKINS, M.R., SETTLE, S.L., STOCKMANN, P.T. & NEEDLEMAN, P. (1990). Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc. Natl. Acad. Sci. U.S.A., 87, 6465 - 6469.
47. WILLENBROCK, R., SCHEUERMANN, M., HOHNEL, K., LUFT, F.C. & DIETZ, R. (1996). Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension. 27, 1259 - 1266.
48. ZEIDEL, M.L., SILVA, P., BRENNER, B.M. & SEIFTER, J.L. (1987). cGMP mediates effects of atrial peptides on medullary collecting duct cells. Am. J. Physiol., 252, F551 - F559.